Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skinvisible Pharmaceuticals' sanitizer kills most H1N1

This article was originally published in The Tan Sheet

Executive Summary

The Las Vegas-based firm says its hand sanitizer lotion DermSafe kills/inactivates the H1N1 virus to the same detection level as 70 percent alcohol, as demonstrated in clinical tests by Bioscience Laboratories. Skinvisible says the outcome confirms an in-vitro study conducted at the European contract research organization Retroscreen Virology, which found the product kills/inactivates 99.9 percent of H1N1. The firm adds the study "proves that Dermsafe is an effective alternative to alcohol, without the drying and safety issues." The sanitizer uses the firm's Invisicare polymer delivery system that binds to skin, resisting wash-off for up to four hours. FDA and the Federal Trade Commission have joined forces to crack down on marketing unapproved products making H1N1 claims (1"The Tan Sheet" Oct. 19, 2009)

You may also be interested in...



FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS103580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel